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Abstract 
Background: Prolonged-release fampridine (PR-fampridine, 4-aminopyridine) increases 
walking speed in the timed 25-foot walk test (T25FW) in some patients (timed-walk 
responders) with multiple sclerosis (MS).  
Objective: To explore the effects of PR-fampridine on different aspects of walking function 
and to identify associated gait modifications in subjects with MS. 
Methods: In this prospective, randomized, placebo-controlled, double-blind, phase II study 
(FAMPKIN; clinicaltrials.gov, NCT01576354) subjects received a 6-week course of oral 
placebo or PR-fampridine treatment (10 mg, twice daily) before crossing over. Using 3D-
motion-analysis, kinematic and kinetic parameters were assessed during treadmill walking 
(primary endpoint). Clinical outcome measures included T25FW, 6-minute walk test (6MWT) 
and balance scales. Physical activity in everyday life was measured with an accelerometer 
device. 
Results: Data from 55 patients were suitable for analysis. Seventeen subjects were timed-
walk responders under PR-fampridine. For the total study population and for responders, a 
significant increase in walking speed (T25FW) and distance (6MWT) was observed. Gait 
pattern changes were found at the single-subject level and correlated with improvements in 
the T25FW and 6MWT. Physical activity was increased in responders. 
Conclusion: PR-fampridine improves walking speed, endurance and everyday physical 
activity in a subset of subjects with MS and leads to individual modifications of the gait 
pattern. 
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Introduction 
In multiple sclerosis (MS), walking impairment is a common consequence of the immune-
mediated inflammatory destruction of myelin sheaths, axons and neurons in the human central 
nervous system (CNS). Ambulatory function is rated as most valuable by patients with early 
and advanced MS while subclinical gait abnormalities can be found even in the early stages of 
the disease1, 2. 
MS lesions can occur at different locations within the CNS and may affect the anatomical 
systems important for walking and motor control to varying degrees3. Resultant symptoms, 
including paresis, sensory deficits, spasticity and fatigue, interfere with different aspects of 
walking function such as gait velocity, endurance and balance. Consequently, MS represents a 
particularly heterogeneous disease even at the level of a single, albeit multi-factorial, 
symptom such as walking dysfunction.     
At present, various disease-modifying immunotherapies for MS are available, but treatment 
options to specifically improve MS-related walking disturbances remain limited4, 5. Two 
phase III trials showed that oral administration of prolonged-release fampridine (PR-
fampridine; dalfampridine) increases walking speed in the timed 25-foot walk test (T25FW) 
in a subset of patients with MS (timed-walk responders)6-8. The active substance 4-
aminopyridine (4-AP) leads to improved signal conduction in demyelinated axons via the 
blockade of voltage-gated potassium channels9. This increase in walking speed was first 
observed two weeks after the initiation of treatment, was clinically relevant as indicated by a 
patient-based walking scale (12-item multiple sclerosis walking scale, 12-item WS) and was 
independent of demographic factors or the type of MS8, 10, 11. However, it remains unclear 
how this increased walking speed was achieved, e.g. through improved strength or balance, or 
reduced motor fatigue.  
The objective of the present investigator-initiated phase II trial (“FAMPKIN”) was (1) to 
further characterize the effects of PR-fampridine on different aspects of walking function in 
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subjects with MS, (2) to analyze the relevance of PR-fampridine-induced improvements in the 
patients` daily life and (3) to identify the modification of gait patterns underlying the 
beneficial effects of PR-fampridine. 
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Patients and Methods 
Study participants. Sixty-one outpatients (Figure 1 A) aged 18 to 65 years with a diagnosis 
of relapsing-remitting (RRMS), primary- (PPMS) or secondary-progressive (SPMS) MS12 
were included (Table 1). Patients were recruited at the University Hospital Zurich, 
Switzerland in 2012 and 2013. Participants had a clinically apparent walking impairment 
(e.g., ataxia, paresis of leg muscles or restricted walking duration) but were able to cover a 
distance of at least 50 meters within 6 minutes with or without walking aids. Patients with a 
history of seizure, prior exposure to 4-AP, or other conditions impeding gait, such as cardiac, 
pulmonary or orthopaedic diseases, were excluded. Subjects who experienced MS relapses or 
whose MS therapy changed during the study were excluded from final analyses. Changes in 
concomitant medication and adverse events (AEs) were recorded at each visit. The study was 
conducted in accordance with the guidelines of the Declaration of Helsinki and the Good 
Clinical Practice guidelines and approved by the Zurich cantonal ethics committee and 
Swissmedic. All participants gave written informed consent. Subjects did not receive payment 
for participation in the trial. The trial, named FAMPKIN, was registered at clinicaltrials.gov 
(NCT01576354). Monitoring was conducted by the Clinical Trials Center of the University 
Hospital Zurich, Switzerland.    
Study design. This explorative study was a prospective, single-center, randomized, placebo-
controlled, double-blind, phase II trial with a crossover design (Figure 1 B). After screening, 
13 study visits took place including five baseline visits (visits 0, 1, 2, 7 and 12). After a 
single-blind, placebo run-in period of two weeks, subjects were randomized at a 1:1 ratio to 
receive double-blind treatment with either placebo or 10 mg PR-fampridine every 12 hours 
for six weeks. Patients then all received single-blind placebo treatment for two weeks (wash-
out period), followed by another six weeks of double-blinded treatment. Subjects who 
received PR-fampridine during the first double-blind treatment period received placebo in the 
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second period and vice versa (crossover). A two-week observation period was maintained 
after the second treatment period. Blinding and randomization was performed by the Zurich 
cantonal pharmacy. All subjects and staff were blinded to treatment assignments. PR-
fampridine matrix tablets and matching placebo tablets were provided by Biogen. Subject 
treatment compliance was confirmed by counting the tablets remaining in the returned boxes. 
Outcome measures. Clinical assessments, questionnaires, activity monitoring and gait 
analyses were performed at different time points as illustrated in Supplementary Table 1. 
Clinical walking and balance tests including the T25FW, 6-minute walk test (6MWT), the 
timed up-and-go test (TUG), Berg balance scale (BBS) and dynamic gait index (DGI) and the 
lower extremity manual muscle test (LEMMT) were conducted as reported previously6, 7, 13-17. 
Subjects who used walking aids in the clinical tests at screening continued to use the same 
devices for all subsequent tests. Timed-walk responders were subjects with a faster walking 
speed in the T25FW for at least three of the four visits during the double-blind treatment 
periods as compared with the maximum speed achieved in the five baseline visits6, 7. Patients’ 
perception of their treatment’s effects was evaluated using the 12-item WS for walking 
function (maximal score of 60 points)18 and the Wurzburg Fatigue Inventory for Multiple 
Sclerosis for motor and cognitive fatigue (WEIMuS; maximal score for cognitive fatigue 36 
points, motor fatigue 32 points)19.  
Subjects were asked to wear an accelerometer device (Actiwatch 2, Philips Respironics, USA) 
attached to the ankle of the more impaired leg (based on the neurological examination) for 14 
consecutive days during each of the two double-blind treatment phases and to keep a sleep 
diary over this period. The device was a small piezo-electric acceleration sensor with a 
sensitivity of 0.025 G and a sampling rate of 32 Hz. Using the Actiware software (V6.0.1), 
motion was measured in activity counts averaged over 15-second intervals20.      
Three-dimensional gait analysis was conducted while walking on an instrumented treadmill 
(120 Hz, FDM-THM-M System, zebris Medical GmbH, Germany) using 14 infrared cameras 
PR-fampridine improves walking function in MS 
 
 
(Vicon, UK) with a sampling rate of 200 Hz. Small reflective markers attached to the 
subjects’ skin overlying anatomical landmarks at the trunk, the upper and lower extremities 
allowed for 3-dimensional reconstruction of movements using a full-body gait model (Plug-
in-Gait, Vicon, UK). Vertical ground reaction force data were exported from the treadmill’s 
integrated capacitive pressure platform21 normalized to body weight and the area under the 
force curve determined using a custom-made Matlab script (Mathworks, Inc., USA). Gait 
analysis was performed twice during each double-blind treatment period (Supplementary 
Table 1). Subjects walked barefoot on the horizontal treadmill and were continuously secured 
by a fall-stop system. Treadmill speed was set to 80% of the mean maximal overground 
walking speed as assessed in the T25FW at Visit 0 and 1. Treadmill speed and other 
conditions (e.g., use of handrails) were kept constant for all sessions for each subject. Gait 
was assessed over a period of 30 seconds per visit (10-20 step cycles). Analysis comprised 15 
of the most relevant kinematic and kinetic gait parameters and was conducted in Vicon Nexus 
(V1.8.5) and ProCalc (Vicon, UK)2, 22-24. A significant change in kinematic parameters under 
treatment with PR-fampridine was defined as the study’s primary endpoint. T25FW 
(including responder status), 6MWT, TUG, BBS, DGI, LEMMT, 12-item WS, WEIMuS, 
accelerometer data and sleep duration were defined as secondary outcomes. 
Safety assessments included a physical examination, resting electrocardiogram, vital signs 
and laboratory tests comprising haematology, blood chemistry and urine analysis 
(Supplementary Table 1). 
Statistics. Statistical analysis was performed with SPSS (V21, IBM Corp., USA), GraphPad 
Prism 5 (V5.01, GraphPad Software, Inc., USA) and Matlab (Mathworks, Inc., USA). For 
data presentation, groups of all subjects, fampridine-responders and fampridine- and placebo-
non-responders were designated. Fisher's exact test was applied to determine significant 
differences in the incidence of AEs under treatment with placebo and PR-fampridine. For 
clinical gait measures, activity parameters, fatigue, sleep duration, kinematic and kinetic 
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parameters, two-tailed, paired t-tests  were performed to detect differences between placebo 
and PR-fampridine treatment. Holm's sequential Bonferroni procedure was applied to adjust 
for multiple comparisons. Repeated measures one-way ANOVA was used to analyse changes 
of walking speed (T25FW) over time in the responder subgroup. To reduce dimensionality of 
the dataset, linearly uncorrelated components (principal components, PCs) were identified 
using an alternating least-squares algorithm on the centred and standardized dataset with 
Kaiser-Guttman stopping criteria25. Each data-point subsequently underwent orthogonal linear 
transformation to determine its loading in PC-space. Translation between treatment conditions 
in the PC-space was quantified for each data pair (patient treated with placebo or PR-
fampridine) in each dimension and group clustering was characterized through volume shifts 
in a fitted convex hull. To test for differences of translations between treatments, a two-tailed 
paired t-test was applied. Changes of kinematic parameters at the single-subject level were 
evaluated by calculating the between-measurement variability (measurement error) within 
each double-blind treatment period for each parameter. Between-measurement variability 
under treatment with PR-fampridine and placebo was similar (Supplementary Table 2), 
therefore an overall mean between-measurement variability was determined for each 
parameter. Changes of kinematic parameters under treatment with PR-fampridine compared 
to placebo exceeding the threshold of the between-measurement variability ± 2 standard 
deviations were defined as relevant.  
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Results 
We assessed 131 subjects with MS for eligibility, of whom 64 subjects were screened and 61 
randomly assigned to treatment (Figure 1 A). One subject withdrew before completing the 
second double-blind treatment period. Sixty patients completed the trial. Five subjects were 
excluded from final analysis (one MS relapse, one subject broke his leg and, three 
noncompliance with the study drug). Data from 55 patients was thus available for analysis. 
Oral administration of PR-fampridine for six weeks was well tolerated and showed no 
significant side-effects compared to placebo treatment (Table 2). In the T25FW, 17 of 55 
subjects (31%) met the timed-walk responder criterion6, 7 under treatment with PR-fampridine 
(fampridine-responders; Figure 2). The number of responders was similar in both study arms 
(8 vs. 9 subjects). Three subjects met the responder criterion only under placebo (placebo-
responders) while five did so during both treatment periods (double-responders); these groups 
were not classified as responders. Thirty subjects were classified as non-responders (55%). 
Compared to baseline performance, responders showed a mean increase of walking speed of 
14% in the T25FW under PR-fampridine. This gain was significantly higher than the 2% 
increase in walking speed observed under placebo (p<0.0001) and was already present one 
week after the initiation of treatment (Figure 2 B, C). Significantly increased walking speed 
under PR-fampridine persisted as an effect when determined for the entire study population 
(p<0.0001; 9% change from baseline), but was not evident in the non-responder group when 
analyzed alone. Walking distance in the 6MWT increased significantly for all patients under 
treatment with PR-fampridine (p<0.0001 compared to placebo; 4% change from baseline; 
Figure 2 D). This effect was more pronounced in the responders (p=0.0004 compared to 
placebo; 8% change from baseline). Treatment with PR-fampridine did not induce significant 
changes in the other clinical tests comprising the TUG (Figure 2 E), LEMMT, BBS and DGI 
or in the 12-item WS (Supplementary Figure 1). For the total study population, no 
significant changes in cognitive or motor fatigue were detected during treatment with PR-
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fampridine (Supplementary Figure 2 A, B). There was a trend towards a reduction in 
cognitive (p=0.253) and, especially, motor (p=0.0534) fatigue in the responders under 
treatment with PR-fampridine. Sleep duration tended to be slightly shorter (about 12 minutes 
per day in the total study population; p=0.0294) under PR-fampridine (Supplementary 
Figure 2 C).  
One subject declined to wear the accelerometer, leaving 54 datasets for analysis. Physical 
activity assessed with this device was not significantly altered by PR-fampridine in the total 
study population, but showed a significant increase in activity counts per day during the 
waking phase in responders (p=0.0045; Figure 3 A, B). The cumulative time spent active per 
day did not differ in subjects between PR-fampridine and placebo treatment in any group, 
indicating that the increase in activity counts is driven by intensity rather than duration of 
physical activity in responders (Figure 3 C).  
One subject was unable to walk on the treadmill at 80% of his overground T25FWT speed 
and was excluded from the kinematic and kinetic analysis (n=54). Compared to placebo, 
averaged group values of most of the kinematic and kinetic measures assessed during 
treadmill walking were not altered by PR-fampridine (Table 3). In the total study population, 
there was a statistically significant increase of knee range of motion (ROM) in the more 
(MIL; p<0.0001) and the less impaired (LIL; p=0.0006) leg during treatment with PR-
fampridine. However, these changes were small, with a difference in ROM of only 2 degrees. 
Alternating least-squares identification of principal components (PC) revealed three 
components with eigenvalues greater than 1 which together accounted for about 90% of the 
total variance (Supplementary Figure 3). Translation between treatments was not 
significantly different between groups on any component. Point dispersion and centroid 
location was similar for placebo and PR-fampridine treatment. Thus, PC analysis showed no 
significant changes under treatment with PR-fampridine in comparison to placebo at the 
group-level.  
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At the single-subject level, we observed heterogeneous fampridine-induced modifications of 
the gait pattern in a subset of patients. Some individuals showed a strongly increased ROM in 
the knee under PR-fampridine (Figure 4 A-C; subject #31 in Figure 5 A, B) while other 
subjects, for instance, demonstrated a greater ROM in the hip joint (subject #9 in Figure 5 A, 
B). Using the between-measurements variability ± 2 standard deviations as a threshold, 
single-subject analysis showed that 25 of the 54 subjects (46%) demonstrated relevant 
changes in at least one gait parameter (Figure 5 B). Type and magnitude of modifications 
differed considerably across subjects and were not restricted to the more or the less impaired 
leg. Proportionally more subjects with at least one altered parameter under PR-fampridine 
were in the responder than the non-responder subgroup (Figure 5 C). Subjects with at least 
one changed kinematic parameter under treatment with PR-fampridine demonstrated 
significantly larger increases of walking speed in the T25FW (two-tailed unpaired t-test: 
p=0.0066, Figure 5 D) and walking distance in the 6MWT (two-tailed unpaired t-test: 
p=0.0114, Figure 5 E) than subjects without such gait pattern changes, indicating that 
walking improvements under PR-fampridine are based on individual modifications of the gait 
pattern. 
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Discussion 
The objective of this explorative, investigator-initiated phase II trial was to characterize the 
effects of PR-fampridine on different aspects of walking impairment in subjects with MS, 
using a comprehensive gait analysis protocol including clinical tests, questionnaires and 
biomechanical parameters. Since MS is a chronic condition and PR-fampridine has a half-life 
in the range of a few hours26, we chose a crossover study design to compensate for the limited 
number of eligible subjects in this single-center trial. A wash-out period of two weeks 
appeared to be sufficient to avoid carryover effects (see Figure 2 B).  
We found that roughly one third of the patients met the timed-walk responder criterion 
defined by Goodman et al. under treatment with PR-fampridine, in line with the results from 
the previous pivotal trials6, 7. Walking speed increased in responders by an average of 14% in 
the T25FW under treatment with PR-fampridine, a somewhat smaller effect than the 20-25% 
increase reported for responders in the larger pivotal trials8. This difference in effect sizes 
may explain the absence of a significant change in the related patient-based outcome measure 
of walking function. In the previous trials, the 12-item WS was used to show that the effects 
of PR-fampridine were clinically meaningful6, 7, 10, 11. In the present study, clinical relevance 
of the observed improvements was demonstrated by the accelerometer data, showing for the 
first time that treatment with PR-fampridine enhances physical activity in everyday life in 
responders. However, the type of physical activity (e.g. walking, running, climbing stairs) that 
increased with PR-fampridine could not be determined with our device. We also demonstrated 
that PR-fampridine not only increased maximal walking speed, but also the walking distance 
achieved in the 6MWT, indicating improved walking endurance27. There was no effect of the 
study drug on static and dynamic balance, which is in contrast to findings from the recent 
MOBILE trial28. Factors limiting the use of the BBS and the DGI scores as outcome measures 
in the present study may include its small sample size (n=55) and the low sensitivity and 
inherent ceiling effects of such scales. 
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The main objective of the present study was to uncover the functional mechanisms that drive 
improvements in the T25FW and 6MWT. We used gold standard 3D-gait analysis to identify 
mechanisms underlying gait disturbances29. There was only a single common effect of PR-
fampridine treatment; a significant increase of the ROM in the knee joint. However, this 
ROM change was minor, casting doubt on its clinical relevance and contribution to the 
observed improvements. Using a descriptive statistical approach based on the between-
measurement variability to evaluate treatment effects at the single-subject level, we observed 
extensive but heterogeneous alterations of the biomechanical parameters in about half of 
subjects. The incidence of gait parameter changes significantly correlated with improvements 
in the T25FW and 6MWT under treatment with PR-fampridine. Subjects with MS can 
experience a variety of neurological impairments and this heterogeneity may also be reflected 
in MS-related gait disturbances where different aspects of ambulatory function can be 
affected to varying degrees. In our cohort, subjects were affected with a wide range of gait 
disturbances characterized by, for example, spasticity, sensory and cerebellar ataxia, or 
weakness of the leg muscles. Therefore, the individual kinematic adaptations observed in our 
data during treatment with PR-fampridine may be anchored in both deficit-specific 
improvements and individual compensatory strategies.  
Finally, the safety data of our trial confirmed good tolerability of PR-fampridine6, 7. In the 
earlier trials, urinary tract infections (UTIs) occurred more frequently in patients treated with 
PR-fampridine in comparison to placebo6, 7. We did not observe a higher incidence of UTIs, 
in line with the findings of a recently published post hoc analysis30.  
To conclude, our findings indicate that treatment with PR-fampridine is well tolerated and 
improves walking speed, endurance and physical activity in a subset of subjects with MS. 
Improvements of ambulatory function are achieved through individual modification of the 
gait pattern.  
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Figure and Table legends 
Figure 1. Patient disposition and study design.  
(A) Flow diagram indicating number of patients assessed, screened, enrolled, randomized and 
analyzed. Reasons for early termination and exclusion from final analysis are given in the 
white boxes. (B) Study design and time schedule. Study visits are indicated by circles. 
Abbreviations: S, Screening Visit.  
Table 1: Patient demographics and disease characteristics.  
Abbreviations: SD, standard deviation; EDSS, expanded disability status scale.  
Table 2: Summary of adverse events (AE) and serious adverse events (SAE).  
Absolute numbers of AEs that occurred during 6 weeks of double-blind placebo and PR-
fampridine treatment in 58 subjects are presented. Incompliant subjects were excluded from 
this analysis The total number of AEs for the entire study was 224. The most frequent AEs 
(without SAEs) occurring more than once in fampridine-treated patients are listed using 
MedDRA (Medical Dictionary for Regulatory Activities) terms. Statistical analysis 
demonstrated no difference between placebo and PR-fampridine treatment. Abbreviations: 
AE, adverse event; SAE, serious adverse event; NSTEMI, non-ST-segment-elevation 
myocardial infarction. 
Figure 2. Clinical gait tests.  
(A) Number and percentage of patients who classified as responder based on the T25FW test 
results during the two double-blind treatment periods. (B) Results of the T25FW test in the 
fampridine-responder subgroup (n=17) illustrated for each double-blind treatment visit and 
the two study arms (grey: PR-fampridine treatment until Visit 6, followed by placebo until 
Visit 11, n=8; black: placebo until Visit 6, followed by PR-fampridine until Visit 11, n=9). 
The single-blind placebo washout phase between Visit 6 and Visit 7 is not shown. Circles 
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represent group mean values for each time point ± standard error of the mean. For differences 
between time-points, repeated measures one-way ANOVA was performed for each arm 
separately. (C-E) Results of the T25FW, 6MWT and TUG for all patients (n=55), responders 
(n=17) and non-responders (n=30). Bars show group mean values ± standard error of the 
mean. Asterisk indicates significant differences. Abbreviations: Non-Resp., non-responder; 
T25FW, timed 25-foot walk test; 6MWT, 6-minute walk test; TUG, timed up-and-go test. 
Figure 3. Activity during everyday life as assessed with an accelerometer device.  
(A) Day-night-activity profile of a responder (subject #48, 42-years-old female with two 
young children, diagnosis of relapsing remitting MS, EDSS 3.5) over 11 consecutive days 
during the two double-blind treatment periods (left, placebo; right, PR-fampridine). Sleep 
phases are indicated by a dark grey background. Black background marks periods during 
which the device was not worn. Activity counts are illustrated as horizontal black lines. Scale 
bar, 1000 activity counts. (B) Cumulative daily activity counts for all subjects (n=54), 
responders (n=17), and non-responders (n=29). (C) Percentage of time with activity during 
the waking phase. Patient groups as in B. (B, C) Bars show group mean values for placebo 
(white) and PR-fampridine treatment (black) ± standard error of the mean. Asterisk indicates 
significant differences. Abbreviations: Mo, Monday; Tu, Tuesday; We, Wednesday; Th, 
Thursday; Fr, Friday; Sa, Saturday; Su, Sunday; Non-Resp., non-responder; s, seconds.  
Table 3. Kinematic and kinetic parameters assessed during treadmill walking.  
Results for different gait parameters are shown for all subjects, responders, and non-
responders (non-resp.) and expressed as group mean values ± standard deviation. Significant 
differences between treatment with placebo and PR-fampridine are highlighted (bold and 
underlined). Abbreviations: MIL, more impaired leg; LIL, less impaired leg; AUC, area under 
the curve; ns, not significant; sig, significant.  
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Figure 4. Kinematics of a responder during treadmill walking at 80% of maximal 
overground walking speed. 
(A) Averaged sagittal angle trajectory of hip, knee and ankle joints of the more impaired leg 
assessed twice during each of the double-blind treatment periods with placebo (P1, P2; blue) 
and PR-fampridine treatment (F1, F2; red). (B) Averaged toe trajectory during treadmill 
walking under placebo and PR-fampridine as in (A). (C) Stick diagram of the more impaired 
leg illustrates limb excursions during the stance and swing phase under treatment with 
placebo (upper) and PR-fampridine (lower). Continuous arrows indicate direction of the 
treadmill; dotted arrows indicate the direction of leg movement. Abbreviations: deg, degrees.  
Figure 5. Kinematic parameters assessed during treadmill walking for single subjects.  
(A) Colour-coded changes in percent of different kinematic gait parameters (columns) under 
PR-fampridine in comparison to placebo are shown for each subject (rows). Responders are 
indicated by red patient numbers on the right. (B) Illustration of gait changes under treatment 
with PR-fampridine compared to placebo for each subject and parameter based on the 
variability between measurements within the same treatment phase. Increases (red) or 
reductions (blue) that are higher or lower than the calculated and averaged variability between 
measurements (measurement error) ± 2 standard deviations are shown. (C-E) Correlation 
between changes of the gait pattern (as defined in B), responder status and clinical gait tests. 
Asterisk indicates significant differences. Abbreviations: MIL, more impaired leg; LIL, less 
impaired leg; ROM, range of motion; DL, double-limb; BOS, base of support; COV, 
coefficient of variation; SD, standard deviation; Non-Resp., non-responder. 
 
 
 





  
Table 1: Patient demographics and disease characteristics. 
 
Age in years, mean ± SD (range)  
 
48.6 ± 9.8  (27 - 64) 
Gender, number (%)  male  21  (38) 
 
female  34  (62) 
Type of MS, number (%)  relapsing remitting (RRMS) 29  (53) 
 
primary progressive (PPMS)  5  (9) 
 
secondary progressive (SPMS)  21  (38) 
Disease duration in years from 
diagnosis, mean ± SD (range)  
 
11.9 ± 7.4  (1 - 37) 
EDSS, mean ± SD (range)  at baseline  4.9 ± 1.3  (2.5 - 6.5) 
 
at last visit  5.1 ± 1.3  (2.5 - 6.5) 
Concomitant MS treatment,  
number (%)  total  34  (62) 
 
with an interferon  9  (16) 
 
with glatiramer acetate  2  (4) 
 
with natalizumab  21  (38) 
 
with fingolimod  2  (4) 
 
  
Table 2: Summary of adverse events (AE) and serious adverse events (SAE). 
 
 
Placebo 
(6 weeks) 
Fampridine 
(6 weeks) 
Total number of AEs  67 74 
Severity  
   Mild  45 54 
   Moderate  21 17 
   Severe  1 3 
Relation to treatment  
   Unlikely  8 6 
   Possible  59 68 
Total number of SAEs  1 2 
   Myocardial infarction  
   (subacute NSTEMI)  0 1 
   Atrial flutter  1 0 
   Ankle fracture  0 1 
Most frequent AEs  
Nervous system disorders  
   Total  16 21 
   Headache  5 7 
   Dizziness  4 3 
   Sciatica  2 3 
   Vertigo  1 2 
Gastrointestinal disorders  
   Total  17 11 
   Nausea  5 4 
   Abdominal pain  4 3 
Renal and urinary disorders  
   Total  11 13 
   Urinary tract infection  9 9 
Respiratory, thoracic and  
mediastinal disorders  
   Total  7 8 
   Cough  2 3 
   Nasopharyngitis  3 2 
Investigations  
   Total 1 5 
   Transaminases increased  1 2 
 
 
 
 
  
Table 3. Kinematic and kinetic parameters assessed during treadmill walking.  
 
Spatio-temporal gait parameters 
 
Measures of stability and trunk movements 
 
Placebo Fampridine P-value Sig. 
  
Placebo Fampridine P-value Sig. 
Duration of stance phase MIL (% of step cycle) 
 
Double-limb support (% of step cycle) 
All subjects (n=54) 67±5 67±5 0.0081 ns 
 
All subjects (n=54) 35±9 36±10 0.0091 ns 
Responder (n=17) 67±4 67±4 0.0920 ns 
 
Responder (n=17) 35±8 36±8 0.1514 ns 
Non-Resp. (n=30) 66±5 66±5 0.0429 ns 
 
Non-Resp. (n=30) 34±9 34±9 0.0884 ns 
Duration of stance phase LIL (% of step cycle) 
 
Base of support (mm) 
All subjects (n=54) 68±4 69±5 0.0824 ns 
 
All subjects (n=54) 117±40 115±44 0.5909 ns 
Responder (n=17) 68±4 69±4 0.1346 ns 
 
Responder (n=17) 120±49 119±53 0.7696 ns 
Non-Resp. (n=30) 68±4 68±5 0.8192 ns 
 
Non-Resp. (n=30) 118±35 117±38 0.7335 ns 
Step length MIL (mm) 
 
Length of C7 trajectory (mm) 
All subjects (n=54) 469±130 472±129 0.3305 ns 
 
All subjects (n=54) 226±83 220±91 0.1283 ns 
Responder (n=17) 474±112 478±115 0.4771 ns 
 
Responder (n=17) 255±109 246±122 0.3123 ns 
Non-Resp. (n=30) 481±145 480±144 0.8070 ns 
 
Non-Resp. (n=30) 206±57 194±54 0.0055 ns 
Step length LIL (mm) 
  All subjects (n=54) 467±122 469±126 0.5731 ns 
 
Forces 
Responder (n=17) 484±96 481±100 0.5046 ns 
  
Placebo Fampridine P-value Sig. 
Non-Resp. (n=30) 469±141 469±148 0.9185 ns 
 
Force during stance MIL (AUC normalized to body weight) 
Length of toe trajectory MIL (mm) 
 
All subjects (n=49) 33±12 33±11 0.6840 ns 
All subjects (n=54) 1258±238 1266±246 0.2912 ns 
 
Responder (n=15) 37±18 36±17 0.3261 ns 
Responder (n=17) 1288±217 1292±222 0.8146 ns 
 
Non-Resp. (n=27) 30±4 29±5 0.6277 ns 
Non-Resp. (n=30) 1268±266 1269±282 0.9084 ns 
 
Force during stance LIL (AUC normalized to body weight) 
Length of toe trajectory LIL (mm) 
 
All subjects (n=49) 34±10 34±10 0.1266 ns 
All subjects (n=54) 1288±252 1292±258 0.5866 ns 
 
Responder (n=15) 39±14 37±13 0.0580 ns 
Responder (n=17) 1330±218 1330±230 0.9958 ns 
 
Non-Resp. (n=27) 32±7 31±7 0.1941 ns 
Non-Resp. (n=30) 1297±278 1292±292 0.5128 ns 
  Toe height MIL (mm) 
 
Joint excursions 
All subjects (n=54) 52±25 54±24 0.0500 ns 
  
Placebo Fampridine P-value Sig. 
Responder (n=17) 51±22 51±20 0.9671 ns 
 
Hip range of motion MIL (degree) 
Non-Resp. (n=30) 57±27 59±27 0.0798 ns 
 
All subjects (n=54) 36±8 36±8 0.2799 ns 
Toe height LIL (mm) 
 
Responder (n=17) 38±7 38±7 0.9670 ns 
All subjects (n=54) 55±21 57±22 0.0223 ns 
 
Non-Resp. (n=30) 35±9 36±9 0.2257 ns 
Responder (n=17) 55±19 57±21 0.2347 ns 
 
Hip range of motion LIL (degree) 
Non-Resp. (n=30) 59±23 60±24 0.4162 ns 
 
All subjects (n=54) 40±6 40±6 0.6125 ns 
  
Responder (n=17) 41±7 42±7 0.3616 ns 
Measures of variability 
 
Non-Resp. (n=30) 40±6 39±6 0.1793 ns 
 
Placebo Fampridine P-value Sig. 
 
Knee range of motion MIL (degree) 
Coefficient of variation of length of toe trajectory MIL 
 
All subjects (n=54) 31±13 33±13 <0.0001 sig 
All subjects (n=54) 3.8±1.6 3.8±1.5 0.6703 ns 
 
Responder (n=17) 29±14 31±13 0.0458 ns 
Responder (n=17) 3.3±1.2 3.8±1.2 0.0579 ns 
 
Non-Resp. (n=30) 33±14 35±13 0.0005 sig 
Non-Resp. (n=30) 3.9±1.5 3.9±1.7 0.9235 ns 
 
Knee range of motion LIL (degree) 
Coefficient of variation of length of toe trajectory LIL 
 
All subjects (n=54) 39±9 41±9 0.0006 sig 
All subjects (n=54) 3.6±1.6 3.7±1.8 0.5756 ns 
 
Responder (n=17) 35±9 37±8 0.0578 ns 
Responder (n=17) 3.3±1.4 3.6±1.4 0.5129 ns 
 
Non-Resp. (n=30) 42±8 44±8 0.0232 ns 
Non-Resp. (n=30) 3.8±1.7 3.9±2.1 0.7423 ns 
 
Ankle range of motion MIL (degree) 
Coefficient of variation of double-limb support 
 
All subjects (n=54) 20±6 20±5 0.3792 ns 
All subjects (n=54) 6.2±1.6 6.0±1.9 0.5029 ns 
 
Responder (n=17) 21±7 21±7 0.9601 ns 
Responder (n=17) 5.9±1.8 6.0±2.4 0.7116 ns 
 
Non-Resp. (n=30) 20±5 19±5 0.1424 ns 
Non-Resp. (n=30) 6.3±1.5 6.0±1.7 0.3138 ns 
 
Ankle range of motion LIL (degree) 
Coefficient of variation of base of support 
 
All subjects (n=54) 22±7 21±7 0.3509 ns 
All subjects (n=54) 30±18 29±23 0.8942 ns 
 
Responder (n=17) 21±6 20±7 0.3199 ns 
Responder (n=17) 30±20 32±37 0.6668 ns 
 
Non-Resp. (n=30) 22±7 22±7 0.5576 ns 
Non-Resp. (n=30) 30±18 29±15 0.7748 ns 
  Coefficient of variation of length of C7 trajectory 
 
Mean treadmill velocity in km/h (80% of T25FW) 
All subjects (n=54) 9.5±3.6 9.0±2.8 0.2810 ns 
 
All subjects (n=54) 3.2±1.4 
   Responder (n=17) 10.2±4.5 9.0±2.8 0.2042 ns 
 
Responder (n=17) 3.0±1.3 
   Non-Resp. (n=30) 9.2±2.9 9.2±3.0 0.9473 ns 
 
Non-Resp. (n=30) 3.4±1.5 
 
0.3136 ns 
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Suppl. Table 1: Schedule of study assessments. 
 
 
Footnotes: 1. MS history includes type of MS, clinical course of MS, current MS signs and symptoms and MS treatment history. 
2. Vital signs include supine systolic and diastolic blood pressure, pulse rate and body temperature. 3. Only in women with 
childbearing potential. 4. The T25FW was performed twice with assistance (if required) and twice without assistance (if 
possible). The TUG was performed once with assistance (if required) and once without assistance (if possible). The 6MWT was 
performed only once, either with or without assistance. Subjects using an assistive device during the first tests (i.e., at the 
screening visit) continued to use the same device for all subsequent tests. 5. The walking speed on the treadmill was based on 
the individual maximal walking speed measured in the T25FW at visit 0 and 1 (80%). 6. Test run to familiarize subjects with the 
setup without assessment of gait parameters.  
Abbreviations: S, screening; V, visit; d, day; EDSS, expanded disability status scale; MS, multiple sclerosis; ECG, 
electrocardiogram; AE, adverse events; SAE, serious adverse events; T25FW, timed 25-foot walk test; 6MWT, 6-minute walk 
test; TUG, timed up-and-go test; BBS, Berg balance scale; DGI, dynamic gait index; BMRC, British Medical Research Council 
scale; LE, lower extremity; 12-item WS, 12-item multiple sclerosis walking scale; WEIMuS, Wurzburg Fatigue Inventory for 
Multiple Sclerosis. 
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Suppl. Table 2. Variability between measurements for the assessed kinematic 
parameters. 
 
 
*   Group average of changes (absolute value) in % between two measurements within one treatment period  
**  Result of paired t-test (placebo vs. Fampridine) after Bonferroni correction.  
 
Difference (in percent) between the two measurements within the same treatment period for the placebo- and PR-fampridine 
phase separately (gray numbers). Note that there was no significant difference of the variability between measurements 
(measurement error) for the two treatment periods for all parameters. Therefore, total mean values (black) derived from 
averaging the results for both treatment periods were used to estimate the general variability between measurements for the 
kinematic parameters. Abbreviations: Sig., significant; ns, not significant; MIL, more impaired leg; LIL, less impaired leg, CoV, 
coefficient of variation.  
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Suppl. Figure 1: Additional clinical tests and walking questionnaire. 
 
 
(A-E) Results of LEMMT, 12-item WS, BBS, and DGI for all patients (n=55), responders (n=17) and non-responders (n=30). 
Note that for the 12-item WS, a score reduction indicates improvement. Legend illustrates color code for placebo (white) and 
PR-fampridine treatment (black). Bars show group mean values ± standard error of the mean. Abbreviations: Non-Resp., non-
responder; LEMMT, lower extremity manual muscle test; MIL, more impaired leg; LIL, less impaired leg; 12-item WS, 12-item 
multiple sclerosis walking scale; BBS, Berg balance scale; DGI, dynamic gait index; mod. BMRC, modified British Medical 
Research Council. 
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Suppl. Figure 2: Fatigue and sleep duration. 
 
 
(A) Results for cognitive fatigue as assessed with the WEIMuS questionnaire. Changes from baseline are presented for all 
subjects (n=55), responders (n=17), and non-responders (n=30) for each of the two double-blind treatment periods. Note that a 
reduction (in points) indicates less fatigue. In all groups, there were no significant changes in cognitive fatigue during PR-
fampridine treatment in comparison to placebo. (B) Results of motor fatigue as assessed with the WEIMuS questionnaire for 
patient groups as in (A). (C) Patients kept a sleep diary for 14 days during each of the two double-blind treatment periods. Mean 
sleep duration per day is presented in minutes for all subjects (n=54), responders (n=17), and non-responders (n=29). Bars 
show group mean values ± standard error of the mean. Abbreviations: Non-Resp., non-responder; WEIMuS, Wurzburg Fatigue 
Inventory for Multiple Sclerosis. 
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Suppl. Figure 3: Principal components of kinematic and kinetic gait 
parameters. 
 
 
(A) Specific loading of each variable on the three main principal components. Conditions are depicted with a grouping of all (B), 
responders (C) and non-responders (D) in the same PC-space. Series 1 shows a negligible effect of treatment (PR-fampridine 
vs. placebo) on location in PC-space independent of grouping. The associated bar graphs indicate non-significant mean 
translation in each dimension ± standard deviation. Series 2 and 3 illustrate this translation in two-dimensional PC-space for 
each individual and component. Note that the orientation of translation is unique for each data-pair. (E) Explained variance of 
the three applicable PCs identified by the stopping criteria. Abbreviations: PC, principal component; MIL, more impaired leg; LIL, 
less impaired leg; CoV, coefficient of variance. 
